HEALTH CARE
<i> Times Staff and Wire Reports</i>
Rhone-Poulenc Seeks OK of Drug: The Collegeville, Pa.-based pharmaceutical company said it submitted a new-drug application to the Food and Drug Administration after two clinical trials showed Rilutek to be effective in treating Lou Gehrig’s disease, technically known as amyotrophic lateral sclerosis, or ALS. The neuromuscular disease attacks nerve cells in the brain and spinal cord, resulting in muscle paralysis and respiratory failure.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
